U.S. Markets close in 1 hr 18 mins
  • S&P 500

    3,675.32
    +53.69 (+1.48%)
     
  • Dow 30

    29,924.96
    +286.32 (+0.97%)
     
  • Nasdaq

    12,391.76
    +193.02 (+1.58%)
     
  • Russell 2000

    1,841.19
    +21.38 (+1.17%)
     
  • Crude Oil

    44.55
    -0.79 (-1.74%)
     
  • Gold

    1,817.90
    +37.00 (+2.08%)
     
  • Silver

    24.07
    +1.48 (+6.54%)
     
  • EUR/USD

    1.2053
    +0.0118 (+0.9883%)
     
  • 10-Yr Bond

    0.9310
    +0.0870 (+10.31%)
     
  • Vix

    20.44
    -0.13 (-0.63%)
     
  • GBP/USD

    1.3424
    +0.0093 (+0.6940%)
     
  • USD/JPY

    104.4220
    +0.0980 (+0.0939%)
     
  • BTC-USD

    18,961.24
    -438.53 (-2.26%)
     
  • CMC Crypto 200

    372.29
    -7.57 (-1.99%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,787.54
    +353.92 (+1.34%)
     

Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

·1 min read

Management to host a conference call and webcast at 4:30 PM ET on that day

Novus Therapeutics, Inc. ("Novus") (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.

Conference Call Details

Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time

Toll Free:

877-407-3982

International:

201-493-6780

Conference ID:

13713171

Webcast:

http://public.viavid.com/index.php?id=142451

About Novus Therapeutics

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.

Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201110006234/en/

Contacts

Media
Amanda Sellers
asellers@vergescientific.com
301-332-5574

Investors
Bruce Mackle
LifeSci Advisors. LLC
bmackle@lifesciadvisors.com
929-469-3859